A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results

Schimanski, C., Kasper, S., Hegewisch-Becker, S., Schröder, J., Overkamp, F., Kullmann, F., Beckstein, W., Vöhringer, M., Öllinger, R., Lordick, F., Heinemann, V., Geißler, M., Schulz-Abelius, A., Linz, B., Bernhard, H., Schoen, M., Greil, R., Smith-Machnow, V., Schmidtmann, I., Moehler, M.

J Clin Oncol 37 (4_suppl)(480). doi:10.1200/JCO.2019.37.4_suppl.480

Abstract